Cargando…

Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer

BACKGROUND: Axillary lymph node metastasis (ALNM) is one of the most important prognostic factors for breast cancer patients, and DNA methylation is involved in ALNM of breast cancer. However, the methylation profile of breast cancer ALNM remains unknown. METHODS: Breast cancer tissues were collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jianguo, Chen, Shaojun, Chen, Jingsen, Zhou, Yige, He, Fei, Wang, Enli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714834/
https://www.ncbi.nlm.nih.gov/pubmed/36454866
http://dx.doi.org/10.1371/journal.pone.0278270
_version_ 1784842320031514624
author Luo, Jianguo
Chen, Shaojun
Chen, Jingsen
Zhou, Yige
He, Fei
Wang, Enli
author_facet Luo, Jianguo
Chen, Shaojun
Chen, Jingsen
Zhou, Yige
He, Fei
Wang, Enli
author_sort Luo, Jianguo
collection PubMed
description BACKGROUND: Axillary lymph node metastasis (ALNM) is one of the most important prognostic factors for breast cancer patients, and DNA methylation is involved in ALNM of breast cancer. However, the methylation profile of breast cancer ALNM remains unknown. METHODS: Breast cancer tissues were collected from patients with and without ALNM. We investigated the genome-wide DNA methylation profile in breast cancer with and without ALNM using reduced representation bisulfite sequencing (RRBS). Then, differentially methylated regions (DMRs) were verified by targeted bisulfite sequencing. RESULTS: A total of 21491 DMRs were identified between the lymph node positive group and negative group. Compared to the LN-negative breast cancer, LN-positive breast cancer had 10,920 hypermethylated DMRs and 10,571 hypomethylated DMRs. Then, 10 DMRs in the gene promoter region were detected by targeted bisulfite sequencing, these gene included HOXA5, PTOV1-AS1, RHOF, PAX6, GSTP1, RASGRF2, AKR1B1, BNIP3, CRMP1, ING5. Compared with negative lymph node, the promoter methylation levels of RASGRF2, AKR1B1 and CRMP1 increased in positive lymph node, while the promoter methylation level of RHOF decreased in positive lymph node. In addition, Cancer Genome Atlas (TCGA) data showed that RASGRF2, AKR1B1 and CRMP1 were low expressed in breast Cancer tissues, while RHOF was high expressed in breast Cancer tissues. Furthermore, in addition to highly methylated AKR1B1, RASGRF2 and CRMP1 gene promoters, BNIP3, GSTP1, HOXA5 and PAX6 gene promoters were also methylated in ER-positive and HER2-negative breast cancer with ALNM. CONCLUSIONS: When compared to negative lymph node breast cancer, the positive lymph node breast cancer has a differential methylation status. Promoter methylation of RASGRF2, AKR1B1, CRMP1 and RHOF in lymph node positive breast cancer tissues was significantly different from that in lymph node negative breast cancer tissues. AKR1B1, RASGRF2, CRMP1, BNIP3, GSTP1, HOXA5 and PAX6 genes were methylated in ER-positive and HER2-negative breast cancer with ALNM. The study provides an important biological base for understanding breast cancer with ALNM and developing therapeutic targets for breast cancer with ALNM.
format Online
Article
Text
id pubmed-9714834
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-97148342022-12-02 Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer Luo, Jianguo Chen, Shaojun Chen, Jingsen Zhou, Yige He, Fei Wang, Enli PLoS One Research Article BACKGROUND: Axillary lymph node metastasis (ALNM) is one of the most important prognostic factors for breast cancer patients, and DNA methylation is involved in ALNM of breast cancer. However, the methylation profile of breast cancer ALNM remains unknown. METHODS: Breast cancer tissues were collected from patients with and without ALNM. We investigated the genome-wide DNA methylation profile in breast cancer with and without ALNM using reduced representation bisulfite sequencing (RRBS). Then, differentially methylated regions (DMRs) were verified by targeted bisulfite sequencing. RESULTS: A total of 21491 DMRs were identified between the lymph node positive group and negative group. Compared to the LN-negative breast cancer, LN-positive breast cancer had 10,920 hypermethylated DMRs and 10,571 hypomethylated DMRs. Then, 10 DMRs in the gene promoter region were detected by targeted bisulfite sequencing, these gene included HOXA5, PTOV1-AS1, RHOF, PAX6, GSTP1, RASGRF2, AKR1B1, BNIP3, CRMP1, ING5. Compared with negative lymph node, the promoter methylation levels of RASGRF2, AKR1B1 and CRMP1 increased in positive lymph node, while the promoter methylation level of RHOF decreased in positive lymph node. In addition, Cancer Genome Atlas (TCGA) data showed that RASGRF2, AKR1B1 and CRMP1 were low expressed in breast Cancer tissues, while RHOF was high expressed in breast Cancer tissues. Furthermore, in addition to highly methylated AKR1B1, RASGRF2 and CRMP1 gene promoters, BNIP3, GSTP1, HOXA5 and PAX6 gene promoters were also methylated in ER-positive and HER2-negative breast cancer with ALNM. CONCLUSIONS: When compared to negative lymph node breast cancer, the positive lymph node breast cancer has a differential methylation status. Promoter methylation of RASGRF2, AKR1B1, CRMP1 and RHOF in lymph node positive breast cancer tissues was significantly different from that in lymph node negative breast cancer tissues. AKR1B1, RASGRF2, CRMP1, BNIP3, GSTP1, HOXA5 and PAX6 genes were methylated in ER-positive and HER2-negative breast cancer with ALNM. The study provides an important biological base for understanding breast cancer with ALNM and developing therapeutic targets for breast cancer with ALNM. Public Library of Science 2022-12-01 /pmc/articles/PMC9714834/ /pubmed/36454866 http://dx.doi.org/10.1371/journal.pone.0278270 Text en © 2022 Luo et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Luo, Jianguo
Chen, Shaojun
Chen, Jingsen
Zhou, Yige
He, Fei
Wang, Enli
Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title_full Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title_fullStr Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title_full_unstemmed Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title_short Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer
title_sort identification and validation of dna methylation markers to predict axillary lymph node metastasis of breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714834/
https://www.ncbi.nlm.nih.gov/pubmed/36454866
http://dx.doi.org/10.1371/journal.pone.0278270
work_keys_str_mv AT luojianguo identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer
AT chenshaojun identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer
AT chenjingsen identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer
AT zhouyige identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer
AT hefei identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer
AT wangenli identificationandvalidationofdnamethylationmarkerstopredictaxillarylymphnodemetastasisofbreastcancer